Cognitive Trial – A Phase III Safety and Efficacy Study of ALZT-OP1 in Individuals with Evidence of Early Alzheimer’s Disease

  • STATUS
    Recruiting
  • sponsor
    AZTherapies
Updated on 23 November 2020
dementia
memantine
acetylcholinesterase
memory impairment
acetylcholinesterase inhibitor
demented

Summary

Cognitive Trial – A Phase III Safety and Efficacy Study of ALZT-OP1 in Individuals with Evidence of Early Alzheimer’s Disease

Description

This Phase III study is designed as a randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The study will evaluate safety and tolerability, efficacy as measured by CDR-SB, and will determine if the combination therapy ALZT-OP1 will slow down, arrests, or reverse cognitive and functional decline in an early stage AD population.

Study visits: Screening, Day 1 (Baseline), Week 4, Week 12, Week 24, Week 48, and Week 72.

Compensation: Contact to Find out More

888-885-0382

www.cognitetrial.com

Details
Condition Alzheimer's Disease
Clinical Study IdentifierTX144012
SponsorAZTherapies
Last Modified on23 November 2020

Eligibility

Yes No Not Sure

Inclusion Criteria

-79 years old
≥ 8 years of education
Study partner is available who has frequent contact with the participant (e.g. an average of 10 hours per week or more), and can accompany the participant to all clinic visits for the duration of the protocol
Evidence of early AD, as defined by all of the following
Memory complaint by subject or study partner that is verified by a study partner
Objective memory impairment for age, documented by scoring below the education adjusted cutoff of the Logical Memory II subscale (Delayed Paragraph Recall) from the Wechsler Memory Scale Third Edition (the maximum score is 25)
≤ 8 for 16 or more years of education, or
≤ 4 for 8-15 years of education
Essentially preserved general cognitive function
Largely intact functional activities
Not demented
Cerebrospinal fluid (CSF) biomarker results consistent with early AD, including CSF Aß-42 levels ≥ 200 pg/mL and ≤ 600 pg/mL
Clinical Dementia Rating (Global) = 0.5; Memory Box score must be at least 0.5
Must be fluent in the language of the cognitive testing material being administered
Stability of permitted medications for 4 weeks prior to study start; subjects receiving acetylcholinesterase inhibitors and/or memantine should be on stable dose of those medications for at least 12 weeks prior to study start with every effort to maintain stable dose for the duration of the study
Visual and auditory acuity adequate for neuropsychological testing
Good general health with no diseases expected to interfere with the study
Must provide written informed consent for APOe4 genotype testing
Must provide written informed consent for CSF sampling

Exclusion Criteria

Any significant neurological disease other than suspected incipient AD, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities
Major depressive episode, as described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) within the past 6 months, which could lead to difficulty complying with the protocol
History of schizophrenia or bipolar disorder (DSM-IV criteria)
History of alcohol or substance abuse or dependence within the past 3 years (DSM-IV criteria)
Currently taking medications that could lead to difficulty complying with the protocol; subjects must be on a stable dose of current medications for 4 weeks prior to study entry, with the exception of acetylcholinesterase inhibitors and/or memantine, which must be on a stable dose for at least 12 weeks prior to study entry
Investigational agents are prohibited one month prior to entry and for the duration of the trial
Currently taking medications known to be CYP2C9 inducers (i.e. carbamazepine and rifampicin)
Currently taking cromolyn, or have taken cromolyn, within the past 12 months
Chronic daily use of high-dose NSAID for osteoarthritis, rheumatoid arthritis, or other chronic inflammatory diseases ("chronic" defined as 3200 mg/day for >2 weeks)
Chronic daily use of aspirin exceeding standard of care guidelines for low dose aspirin therapy for prevention of stroke and/or other recommended uses
Allergy to cromolyn (also known as Intal®, Nasalcrom®, Opticrom®, Gastrocrom®, etc.)
Allergies to ibuprofen (Advil®, Motrin®, Nuprin®, etc.) or aspirin
Clinically significant respiratory disorders with impaired respiratory effort or difficulty taking inhaled drugs
Uncontrolled chronic asthma
Abnormal pulmonary function test, defined for this protocol as: FEV1/FVC < predicted value for subject AND FEV1 < 70% of predicted value, indicating moderate or severe respiratory obstruction
Taking inhaled protein products on a chronic basis
Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol
Pregnancy or lactation for female subjects of child-bearing potential (i.e., < two years post-menopausal or not surgically sterile)
For sexually active male subjects, unwillingness or incapability of using appropriate contraception methods
Severe renal or hepatic impairment
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note